This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.

Regeneron Pharmaceuticals (NASDAQ:REGN) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ ...

To watch more expert insights and analysis on the latest ... Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ...

JPMorgan lowered the firm’s price target on Regeneron (REGN ... particularly as we near a number of pipeline readouts, the analyst tells investors in a research note. Published first on TheFly ...

Ulta Beauty ( ULTA) was the best-performing stock in the S&P 500 after the beauty products retailer beat profit and sales ...

This comprehensive analysis examines Regeneron’s current position, future prospects, and the factors that could shape its trajectory in the coming years. Regeneron focuses on developing and ...

Wall Street analysts issued a fresh round of ratings changes on Friday, including notable downgrades for Airbnb (ABNB), Regeneron (REGN), and Cooper Companies (COO), and upgrades for Unity (U) and ...